Consolidated sales before Clawback & Rebates amounted to €61.10 million compared to €47.74 million in the corresponding period last year, recording an increase of 28%.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Lavipharm announced the key consolidated financial figures for the first nine months of 2026, recording a 12.5% increase in adjusted earnings before interest, taxes, depreciation and amortization (
Consolidated Sales before Clawback & Rebates amounted to Euro 61.10 million compared to Euro 47.74 million in the corresponding period last year, recording an increase of 28%.